Kidron: Oramed collected $30M of $50M Chinese licensing deal
Nadav Kidron · 1187 The Chinese Gave Him $50M For Orally Delivered Insulin Capsul Idea, Will It Take Off? · Oct 24, 2018 · at 4:45
Nadav Kidron, CEO of Oramed Pharmaceuticals, details the cash receipt breakdown for Oramed's $50 million Chinese partnership.
0:00 / 0:07exact quote · 7.7s
720p mp4 · rendered on demand · StarZero watermark
“So we got thirty million dollars out of the 50. We should be getting a few more millions this year, and some of it earlier next year as well.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Nadav Kidron
Kidron: China deal pays Oramed $50M and 10% royalties, implying $1B valuation
“They're paying us fifty million dollars and 10% royalties, and they've been investing hundreds of millions of dollars into the facility of the building in China, and China is five percent of the global market of diabetes, so the value that they gave us, this f…”
Kidron: US public markets hold a bias against China-derived deals
“So I think there's a little bit of a bias in the United States about anything which is China derived.”
Kidron: Oramed will probably enter the Chinese market before the US
“And with the Chinese FDA, we're probably going to get to the market even before the United States.”
Kidron: Oramed will have 90-day oral insulin trial results by August 2019
“And in about 10 months from now, we're going to have the most important milestone in our history. We're going to have the result of a ninety-day trial when we administer oral insulin, and that's going to be a very, or the most clear-cut indication as to the va…”
Kidron: Oral delivery of proven drugs lowers risk versus novel chemicals
“Here, what we do is we're taking insulin that has been around for a long time, and we know that it works, and we have the ability to deliver it orally instead of an injection that we already proved in principle that that works. So that's why I think while ther…”
Kidron: Future Oramed deals will price on potential, not market cap
“Now we are, and this is public in our filing, we are in discussions with potential partners And I think everybody understands that if we're going to do a deal, if we're going to strike a deal, it's not going to be based on the current market cap, but it's goin…”